Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships.
Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Among authors: drewry dh. bioRxiv [Preprint]. 2023 Dec 28:2023.12.28.573261. doi: 10.1101/2023.12.28.573261. bioRxiv. 2023. PMID: 38234837 Free PMC article. Updated. Preprint.
Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.
Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME. Matossian MD, et al. Among authors: drewry dh. PLoS One. 2017 Aug 3;12(8):e0177802. doi: 10.1371/journal.pone.0177802. eCollection 2017. PLoS One. 2017. PMID: 28771473 Free PMC article.
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, Rusch DB, Sabol RA, Ucar DA, Zabaleta J, Miele L, Bunnell BA, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: drewry dh. Anticancer Drugs. 2020 Sep;31(8):759-775. doi: 10.1097/CAD.0000000000000962. Anticancer Drugs. 2020. PMID: 32796402 Free PMC article.
Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review.
Matossian MD, Wells CI, Zuercher WJ, Collins-Burow BM, Drewry DH, Burow ME. Matossian MD, et al. Among authors: drewry dh. Curr Med Chem. 2021;28(30):6096-6109. doi: 10.2174/0929867328666210322101749. Curr Med Chem. 2021. PMID: 33749548 Review.
Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells.
Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: drewry dh. Oncol Lett. 2021 May;21(5):380. doi: 10.3892/ol.2021.12641. Epub 2021 Mar 16. Oncol Lett. 2021. PMID: 33777204 Free PMC article.
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
Matossian MD, Elliott S, Van Hoang T, Burks HE, Wright MK, Alzoubi MS, Yan T, Chang T, Wathieu H, Windsor GO, Hartono AB, Lee S, Zuercher WJ, Drewry DH, Wells C, Kapadia N, Buechlein A, Fang F, Nephew KP, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: drewry dh. Breast Cancer Res Treat. 2021 Aug;189(1):49-61. doi: 10.1007/s10549-021-06295-4. Epub 2021 Jul 1. Breast Cancer Res Treat. 2021. PMID: 34196902
Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer.
Schirmer AU, Driver LM, Zhao MT, Wells CI, Pickett JE, O'Bryne SN, Eduful BJ, Yang X, Howard L, You S, Devi GR, DiGiovanni J, Freedland SJ, Chi JT, Drewry DH, Macias E. Schirmer AU, et al. Among authors: drewry dh. Mol Ther. 2022 Jan 5;30(1):485-500. doi: 10.1016/j.ymthe.2021.08.029. Epub 2021 Aug 25. Mol Ther. 2022. PMID: 34450249 Free PMC article.
111 results